List of Excipients in Branded Drug MYCAPSSA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chiesi USA Inc	MYCAPSSA	octreotide	10122-550	AMMONIA
Chiesi USA Inc	MYCAPSSA	octreotide	10122-550	FERROSOFERRIC OXIDE
Chiesi USA Inc	MYCAPSSA	octreotide	10122-550	GELATIN
Chiesi USA Inc	MYCAPSSA	octreotide	10122-550	GLYCERYL MONOCAPRYLATE
Chiesi USA Inc	MYCAPSSA	octreotide	10122-550	MAGNESIUM CHLORIDE
Chiesi USA Inc	MYCAPSSA	octreotide	10122-550	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
Chiesi USA Inc	MYCAPSSA	octreotide	10122-550	POLYSORBATE 80

MYCAPSSA Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: October 1, 2026

MYCAPSSA is an oral delayed-release octreotide capsule developed by Chiasma and commercialized by Amryt Pharma, which was acquired by Chiesi Farmaceutici in 2023. Its commercial value depends on an excipient-enabled delivery system that protects octreotide from gastrointestinal degradation and promotes intestinal absorption. The main opportunity for excipient suppliers is not a conventional inactive-ingredient sale. It is participation in a controlled-release, peptide-delivery platform with regulatory, manufacturing, and intellectual-property barriers.

MYCAPSSA was approved by the U.S. Food and Drug Administration in 2020 for maintenance treatment of acromegaly patients who responded to and tolerated treatment with octreotide or lanreotide. The product is marketed in 20 mg, 40 mg, and 80 mg delayed-release capsule strengths.[1]

What is MYCAPSSA and how does its oral delivery system work?

MYCAPSSA contains octreotide acetate, a synthetic somatostatin analog traditionally administered by injection. Its oral formulation uses enteric-coated pellets and a transient permeability enhancement approach intended to improve absorption in the small intestine.

The formulation must address four technical problems:

1. Protect octreotide from gastric acid and proteolytic enzymes.
2. Release the active ingredient at the intended intestinal site.
3. Improve epithelial permeability without causing unacceptable gastrointestinal toxicity.
4. Maintain dose uniformity and stability across multiple capsule strengths.

The product is therefore an excipient-dependent delivery system rather than a simple immediate-release octreotide capsule. Its performance depends on the interaction between the peptide, pellet matrix, enteric coating, permeability-enhancing excipients, capsule shell, and manufacturing process.

What excipients are used in MYCAPSSA?

FDA labeling identifies octreotide acetate and several inactive ingredients, including magnesium chloride, maltose, povidone, crospovidone, colloidal silicon dioxide, and talc. The capsule and coating system also uses pharmaceutical film-forming and color components identified in the approved labeling.[1]

The excipient roles can be grouped as follows:

Excipient or excipient class	Likely functional role in MYCAPSSA
Magnesium chloride	Supports the oral absorption-enhancement system and may affect ionic strength and permeability
Maltose	Bulking and pellet-processing excipient
Povidone	Binder and granulation aid
Crospovidone	Disintegrant and release-support excipient
Colloidal silicon dioxide	Glidant and powder-flow aid
Talc	Processing aid and coating component
Enteric polymers	Protect the formulation in the stomach and control intestinal release
Capsule-shell materials	Provide dosage-form integrity and patient-use characteristics

The exact commercial opportunity depends on whether an excipient is used as a standard compendial material or is part of the proprietary performance mechanism. Standard fillers and glidants are replaceable. The permeability-enhancement system, pellet architecture, and coating process are much harder to substitute without new comparative dissolution, stability, bioavailability, and clinical evidence.

What excipient strategy protects MYCAPSSA from generic competition?

MYCAPSSA’s excipient strategy creates several layers of differentiation.

Enteric protection

Octreotide is vulnerable to gastrointestinal degradation. An enteric coating delays exposure until the capsule or pellets reach a higher-pH intestinal environment. The coating must balance acid resistance, release timing, mechanical durability, and storage stability.

A generic manufacturer could use a different enteric polymer or coating composition. It would still need to demonstrate comparable release characteristics and bioequivalence under the FDA’s ANDA framework.

Permeability enhancement

The central technical barrier is oral delivery of a peptide with low natural intestinal permeability. MYCAPSSA uses a transient absorption-enhancement approach designed to increase local epithelial permeability for a limited period.

This creates an important distinction between ordinary excipient substitution and functional excipient substitution. A generic formulation may not be able to replace a permeability enhancer solely because the replacement is pharmaceutically acceptable. It would need to show that the change does not alter exposure, tolerability, local gastrointestinal effects, or release behavior.

Multiparticulate dosage form

A pellet-based system can distribute the dose across the gastrointestinal tract and reduce the consequences of local formulation variability. It also gives the manufacturer multiple patentable variables:

• Pellet size distribution
• Drug loading
• Binder concentration
• Coating weight gain
• Enteric polymer selection
• Plasticizer and anti-tacking system
• Release profile
• Capsule fill weight
• Moisture-control conditions

These process variables can create manufacturing know-how even when the listed ingredients are publicly known.

What patents protect MYCAPSSA?

Public patent records associate MYCAPSSA with Chiasma patent families covering oral octreotide formulations, absorption-enhancing compositions, and methods of treating endocrine disorders. U.S. patent numbers publicly associated with the product include U.S. Patent Nos. 9,675,618, 10,610,575, and 11,147,876.[2-4]

Patent family or patent	Publicly associated subject matter	Strategic relevance
U.S. Patent No. 9,675,618	Oral peptide delivery and formulation technology	Supports the core oral-octreotide platform
U.S. Patent No. 10,610,575	Octreotide formulation and delivery claims	May cover composition or dosage-form features
U.S. Patent No. 11,147,876	Later-generation formulation or therapeutic claims	Extends potential protection beyond the earliest family

Patent expiration dates can vary by patent-term adjustment, patent-term extension, terminal disclaimers, and claim-specific scope. The relevant commercial analysis must distinguish between the earliest blocking patent, later formulation patents, and method-of-use patents.

The key patent risks for a generic applicant are likely to involve:

• Oral octreotide compositions
• Enteric-coated dosage forms
• Permeability-enhancing excipient combinations
• Release profiles
• Methods of maintaining octreotide exposure
• Treatment of acromegaly with oral octreotide
• Manufacturing processes for multiparticulate capsules

Patent protection is strongest where the claims require a defined combination of active ingredient, excipient, release profile, and pharmacokinetic result. It is weaker where claims depend only on broad ingredient classes that can be avoided through routine formulation changes.

What is the FDA and Orange Book status of MYCAPSSA?

MYCAPSSA is approved under NDA 214991. The FDA approved the product in June 2020 for maintenance treatment of acromegaly in patients who responded to and tolerated octreotide or lanreotide.[1]

MYCAPSSA received orphan-drug designation for acromegaly. Orphan-drug exclusivity generally runs for seven years from approval, subject to statutory exceptions. Based on the 2020 approval date, the orphan-exclusivity period generally extends into 2027.[5]

The Orange Book analysis should separate three forms of protection:

Protection type	Relevance to MYCAPSSA
Orphan-drug exclusivity	Limits approval of the same drug for the same orphan indication during the exclusivity period
Listed patents	May require a Paragraph IV certification or a statement that a generic will wait for patent expiry
Regulatory exclusivity	The original approval included clinical investigation supporting the product’s safety and effectiveness

A listed patent does not necessarily prevent an ANDA filing. A Paragraph IV certification can trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman Act.[6]

When does MYCAPSSA lose exclusivity?

The practical entry date depends on the interaction of orphan exclusivity, listed patents, litigation, and the scope of an ANDA applicant’s proposed label.

The principal timeline is:

Event	Date or expected period
FDA approval of MYCAPSSA	June 2020
Seven-year orphan exclusivity	Generally through 2027
Earliest possible ANDA activity	Before orphan exclusivity expiration, subject to statutory and patent constraints
Potential generic approval	Dependent on patent certifications, litigation, and label scope
Later formulation-patent exposure	Potentially extending beyond orphan exclusivity

Orphan exclusivity is indication-specific. It does not necessarily block every formulation or every use of octreotide. A generic applicant could pursue a carve-out strategy if the protected indication and proposed labeling allow it. The feasibility of that strategy depends on the precise Orange Book-listed method-of-use patents and whether the remaining label would still be medically and commercially viable.

Which companies are challenging MYCAPSSA?

Publicly available information has not established a broad, commercially significant field of approved generic competitors for MYCAPSSA. The competitive threat is more likely to come from future ANDA applicants, alternative octreotide products, injectable somatostatin analogs, and other acromegaly therapies than from an existing oral generic.

Potential applicants would face several entry barriers:

• Demonstrating bioequivalence for a locally acting and systemically absorbed peptide formulation
• Matching the delayed-release profile
• Reproducing absorption enhancement
• Establishing acceptable gastrointestinal tolerability
• Addressing patent claims on formulation and use
• Sourcing consistent pharmaceutical-grade excipients
• Validating multiparticulate coating and capsule-filling processes

No biosimilar pathway is expected to apply. Octreotide is a chemically defined peptide drug rather than a biologic product approved through the 351(k) biosimilar pathway. A competing oral octreotide product would more likely use the ANDA pathway if it could demonstrate pharmaceutical equivalence and bioequivalence, or a full or partial NDA pathway if formulation differences prevented ANDA approval.

What commercial opportunities exist for excipient suppliers?

Functional excipient supply

The most attractive opportunity is supplying excipients that perform a measurable delivery function. Candidates include:

• Permeability enhancers
• Enteric polymers
• Low-moisture binders
• Modified-release coating systems
• Anti-tacking agents
• Capsule-shell materials with controlled moisture transmission
• Excipient systems optimized for peptide stability

Suppliers with regulatory files, global compendial support, and consistent lot-to-lot performance have an advantage over commodity producers.

Second-source qualification

MYCAPSSA’s commercial continuity depends on reliable supply of excipients that meet tight physical and chemical specifications. A qualified second source can reduce supply-chain concentration and support manufacturing resilience.

The most difficult materials to dual-source are those linked to:

• Absorption enhancement
• Coating performance
• Moisture sensitivity
• Pellet mechanical strength
• Octreotide stability
• Dissolution behavior

A supplier can create switching costs by offering formulation-specific technical packages, including particle-size control, residual-solvent data, extractables and leachables data, stability studies, and process-validation support.

Generic design-around products

Generic manufacturers may seek non-infringing alternatives to the proprietary excipient system. This creates opportunities for suppliers of replacement polymers, binders, permeability enhancers, and coating technologies.

The commercial value of a design-around excipient is highest when it can deliver:

• Equivalent or superior intestinal release
• Lower variability in octreotide exposure
• Reduced gastrointestinal tolerability risk
• Lower coating-process complexity
• Better global regulatory acceptability
• A distinct patent position

Lifecycle management

The product owner can extend commercial differentiation through new dosage forms, administration instructions, lower-dose strengths, pediatric or special-population studies, and manufacturing improvements. Excipient suppliers that participate early in lifecycle programs may obtain longer supply commitments than suppliers of standard capsule ingredients.

How strong is the MYCAPSSA patent estate?

The estate appears stronger at the formulation and delivery-system level than at the active-ingredient level. Octreotide itself is an established molecule with extensive prior art. The defensible value lies in making oral delivery practical.

Estate component	Relative strength
Octreotide active ingredient	Low, because the molecule is established
Oral peptide delivery	Moderate to strong, depending on claim breadth
Enteric-coated multiparticulate system	Moderate
Permeability-enhancing excipient combination	Potentially strong
Acromegaly method-of-use claims	Moderate, but vulnerable to label carve-outs
Manufacturing know-how	Strong commercially, even if not fully patent-protected
Orphan exclusivity	Strong until the statutory period expires

The principal weakness is that formulation patents can often be challenged through excipient substitution, altered coating architecture, or a different release profile. The principal strength is that a successful design-around must still meet the demanding bioequivalence and product-quality requirements of an oral peptide drug.

What generic launch scenarios exist for MYCAPSSA?

Three scenarios are commercially plausible.

Scenario one: delayed entry after orphan and patent protection

A generic applicant waits until the principal patents and orphan exclusivity no longer create a meaningful blocking position. This minimizes litigation risk but allows the branded product to build prescriber and payer relationships.

Scenario two: Paragraph IV challenge

An applicant files an ANDA with Paragraph IV certifications against one or more listed patents. The resulting litigation could trigger a 30-month stay, depending on the timing and statutory requirements. The applicant may pursue invalidity, non-infringement, or both.

Scenario three: formulation-specific NDA competitor

A company develops a materially different oral octreotide product that cannot rely on ANDA equivalence. This route has higher development costs but may avoid some formulation claims and support a separate intellectual-property estate.

The largest near-term competitive pressure may come from injectable octreotide generics and long-acting formulations rather than a direct oral substitute. MYCAPSSA’s commercial proposition is reduced injection burden, so products that improve injection convenience can compete even without duplicating the oral formulation.

How does MYCAPSSA compare with injectable octreotide?

Attribute	MYCAPSSA	Injectable octreotide
Route	Oral delayed-release capsule	Subcutaneous or long-acting injectable
Main technical issue	Peptide stability and intestinal absorption	Injection delivery and depot performance
Excipient importance	Very high	High, but generally less dependent on intestinal permeability
Generic pathway	Likely ANDA for a qualifying equivalent	ANDA or other abbreviated pathway depending on dosage form
Patient burden	Avoids routine injections	Requires injection or clinic administration
Patent focus	Oral delivery, permeability, enteric release	Depot systems, injection devices, formulations
Main commercial advantage	Oral administration	Established exposure and long clinical history

MYCAPSSA is most defensible where patients and physicians value an oral alternative and where the formulation delivers consistent exposure without injection administration.

Key Takeaways

• MYCAPSSA is an oral delayed-release octreotide product whose value depends heavily on excipient-enabled absorption and enteric protection.
• The most commercially important excipient technologies involve permeability enhancement, enteric coating, multiparticulate processing, and peptide stability.
• Standard fillers and glidants are relatively easy to replace. Functional excipient systems are harder to design around.
• MYCAPSSA was approved in 2020 under NDA 214991 and received orphan-drug exclusivity for acromegaly.
• Publicly associated U.S. patents include 9,675,618, 10,610,575, and 11,147,876.
• Generic competition would likely proceed through an ANDA and could involve Paragraph IV litigation.
• Biosimilar competition is not the expected pathway because octreotide is a chemically defined peptide drug.
• The strongest commercial opportunity for excipient companies is a qualified, regulatory-supported delivery system that can serve either the branded product or a non-infringing generic design-around.

FAQs

What is the most important excipient in MYCAPSSA?

The most strategically important excipient category is the absorption-enhancement system, because oral octreotide requires improved intestinal permeability. Enteric coating materials are also critical because they control where the drug is released.

Can a generic manufacturer use different excipients from MYCAPSSA?

Yes. An ANDA applicant may use different inactive ingredients if the proposed product meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and labeling. A change in a functional excipient may require extensive comparative development work.

Is MYCAPSSA an extended-release drug?

MYCAPSSA is a delayed-release capsule. The dosage form is designed to delay release until the intestinal tract rather than provide conventional long-duration systemic release from an immediate-release product.

What makes oral octreotide difficult to manufacture?

The manufacturer must control peptide stability, pellet drug loading, enteric-coating uniformity, moisture exposure, capsule fill weight, dissolution performance, and absorption variability. Small process changes can affect systemic exposure.

Can a permeability enhancer create new patent protection?

Yes. A defined permeability-enhancing excipient combination, concentration range, release profile, or method of use can support patent claims if it satisfies novelty, non-obviousness, written-description, and enablement requirements.

References

1. U.S. Food and Drug Administration. (2020). MYCAPSSA (octreotide) delayed-release capsules: Prescribing information. https://www.accessdata.fda.gov
2. United States Patent and Trademark Office. (2017). U.S. Patent No. 9,675,618. https://patents.google.com/patent/US9675618
3. United States Patent and Trademark Office. (2020). U.S. Patent No. 10,610,575. https://patents.google.com/patent/US10610575
4. United States Patent and Trademark Office. (2021). U.S. Patent No. 11,147,876. https://patents.google.com/patent/US11147876
5. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/orphan-drug-designation-and-exclusivity
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.